GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy

GM-CSF Sargramostim for Alzheimer's Disease (NCT04902703)

Trial Overview

GM-CSF (Sargramostim) is being investigated in a Phase 2 clinical trial for Alzheimer's disease (AD) as an immunomodulatory therapy that enhances microglial function to promote clearance of amyloid-beta plaques["@gmcsf_trial"]. This represents a fundamental shift in AD therapeutic strategy from targeting amyloid directly to instead empowering the brain's native immune system to clear pathological deposits.

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as sargramostim (Leukine®), is a recombinant human cytokine approved by the FDA for use in neutropenia and bone marrow transplantation. Its use in Alzheimer's represents therapeutic repurposing based on compelling preclinical data demonstrating its ability to enhance microglial function and reduce amyloid burden.

Trial Details

GM-CSF Sargramostim for Alzheimer's Disease (NCT04902703)

Trial Overview

GM-CSF (Sargramostim) is being investigated in a Phase 2 clinical trial for Alzheimer's disease (AD) as an immunomodulatory therapy that enhances microglial function to promote clearance of amyloid-beta plaques["@gmcsf_trial"]. This represents a fundamental shift in AD therapeutic strategy from targeting amyloid directly to instead empowering the brain's native immune system to clear pathological deposits.

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as sargramostim (Leukine®), is a recombinant human cytokine approved by the FDA for use in neutropenia and bone marrow transplantation. Its use in Alzheimer's represents therapeutic repurposing based on compelling preclinical data demonstrating its ability to enhance microglial function and reduce amyloid burden.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04902703 |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | University of Miami |
| Intervention | GM-CSF (Sargramostim) |
| Indication | Mild Cognitive Impairment due to AD, or mild AD dementia |
| Enrollment | Approximately 80 patients |
| Duration | 6 months treatment + 6 months follow-up |

Mechanism of Action

GM-CSF Biology

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that plays a critical role in the proliferation, differentiation, and activation of myeloid cells[@potts2012]. In the central nervous system, GM-CSF acts primarily on microglia—the brain's resident immune cells—through the GM-CSF receptor (CSF2R), which is expressed abundantly on microglial surfaces.

The mechanisms through which GM-CSF exerts beneficial effects in AD include:

Therapeutic Rationale

The rationale for GM-CSF in AD is based on a fundamental observation: the brains of AD patients show evidence of insufficient microglial activation[@marchetti2022]. Despite the presence of abundant amyloid plaques, microglia in AD typically exist in a relatively quiescent state with impaired phagocytic function. This "microglial failure" hypothesis suggests that enhancing microglial activity could help the brain clear amyloid deposits more effectively.

Specifically, GM-CSF may address[@boone2018]:

Preclinical Evidence

The translational rationale for this trial rests on robust preclinical data from multiple laboratories:

• GM-CSF improves cognitive function in multiple AD mouse models (APP/PS1, 3xTg-AD, 5xFAD)
• Treatment increases microglial recruitment to amyloid plaques in vivo
• Reduces amyloid burden by 30-50% in preclinical studies
• Improves synaptic density and neuronal survival
• Enhancement of learning and memory in behavioral testing

Study Design

Eligibility Criteria

Inclusion Criteria:

• Age 55-80 years
• Clinical diagnosis of MCI due to AD or mild AD dementia
• MMSE score 20-26 (inclusive)
• Amyloid positivity on PET or CSF biomarkers (confirmed by Aβ42/40 ratio)
• Stable on acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and/or memantine for at least 3 months
• Willing to undergo repeated neuroimaging and CSF collection

• Significant vascular disease (modified Hachinski score >4)
• Other neurological conditions (stroke, PD, Lewy body dementia, frontotemporal dementia)
• Immunosuppressive therapy or autoimmune conditions
• Cancer within 5 years (excluding non-melanoma skin cancer)
• Active psychiatric disorders (severe depression, schizophrenia)
• Contraindications to MRI or PET imaging

Treatment Regimen

• GM-CSF dose: 125 μg/m² subcutaneously daily
• Duration: 7 days per month for 6 months (total of 42 doses)
• Control: Placebo (saline) with identical subcutaneous administration
• Randomization: 1:1 ratio, stratified by age and baseline MMSE

Outcome Measures

Primary Endpoints:

• Change in ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale) score at 12 months
• Change in MMSE (Mini-Mental State Examination) at 12 months
• Safety and tolerability (adverse events, laboratory values, vital signs)

• CSF amyloid-beta (Aβ40, Aβ42) and tau (total, phosphorylated) levels
• PET amyloid imaging (standardized uptake value ratio)
• Microglial activation markers (PET with TSPO ligand)
• Volumetric MRI (hippocampal and whole brain atrophy rates)
• Clinical Global Impression of Change (CGIC)

• Inflammatory cytokines in CSF and plasma
• Neurodegeneration markers (NFL, NSE)
• Cognitive reserve measures

Clinical Rationale

Microglial Activation in AD

Microglia play a dual role in Alzheimer's disease[@marchetti2022]. Depending on their activation state, they can either contribute to neurodegeneration or protect the brain.

Detrimental microglial function:

• Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) can damage neurons
• Excessive synapse elimination through complement-mediated pathways
• Production of reactive oxygen species that cause oxidative damage

• Phagocytic clearance of amyloid deposits
• Production of neurotrophic factors (BDNF, GDNF)
• Support of synaptic plasticity
• Modulation of neuroinflammation toward resolution

Amyloid Cascade and Microglial Failure

The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptides is the initiating event in AD pathogenesis. However, even in healthy elderly individuals, amyloid deposits can be found in the brain without leading to clinical dementia. This suggests that the brain's clearance mechanisms—in which microglia play a central role—can sometimes keep pace with amyloid production.

In AD, this balance is disrupted. Several factors contribute to microglial failure:

• Chronic exposure to amyloid reduces microglial responsiveness
• Age-related changes in microglial biology
• Genetic factors (TREM2 variants impair microglial function)
• Prolonged neuroinflammation leads to microglial exhaustion

• Activating dormant microglia
• Enhancing phagocytic capacity
• Promoting anti-inflammatory polarization

Comparison with Other Immunotherapy Approaches

GM-CSF differs fundamentally from other AD immunotherapy strategies:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Aβ antibodies (aducanumab, lecanemab) | Passive immunization, peripheral sink | Approved |
| Aβ vaccines (ACI-35, UB-311) | Active immunization | Clinical trials |
| TREM2 agonists | Enhance microglial phagocytosis | Preclinical |
| GM-CSF (this trial) | Immunomodulation, microglial activation | Phase 2 |
| Colony-stimulating factors | Myeloid cell activation | Phase 2 |

The advantage of GM-CSF over antibody-based approaches includes:

• Oral availability (subcutaneous vs. monthly IV infusions)
• Lower cost
• Enhanced endogenous immune response
• Potential for disease modification through multiple pathways

Current Status

The trial has been completed. Results will determine whether GM-CSF warrants further development as an AD therapeutic. Key questions being addressed include:

If positive, this would represent a paradigm shift in AD treatment toward immunomodulatory approaches that enhance the brain's native clearance mechanisms.

Biomarker Monitoring

The trial incorporates comprehensive biomarker monitoring to understand drug effects:

CSF Biomarkers

Cerebrospinal fluid collection enables measurement of:

• Amyloid: Aβ40, Aβ42, Aβ42/40 ratio (reflects brain amyloid burden)
• Tau: Total tau, phosphorylated tau (markers of neurodegeneration)
• Inflammatory: IL-1β, TNF-α, IL-6, TGF-β (microglial activation state)
• synaptic: Neurogranin, SNAP-25 (synaptic integrity)

PET Imaging

• Amyloid PET: 18F-florbetapir or 18F-flutemetamol to quantify plaque burden
• Microglial PET: TSPO ligands to measure in vivo microglial activation
• FDG-PET: Cerebral glucose metabolism as a marker of neuronal function

MRI

• Volumetric MRI: Hippocampal and whole brain atrophy rates
• Diffusion tensor imaging: White matter integrity
• Resting state fMRI: Functional connectivity changes

Safety Considerations

GM-CSF has a well-established safety profile from oncology applications. However, AD patients may have different tolerability:

Common Adverse Effects (expected)

• Injection site reactions (redness, swelling, pain)
• Flu-like symptoms (fever, chills, myalgia)
• Leukocytosis (elevated white blood cell count)
• Bone aches (due to bone marrow stimulation)

Special Considerations in AD

• Potential for increased infection risk in elderly
• Interactions with immunosuppressive AD medications
• Effects on cardiovascular parameters
• Potential for worsening of pre-existing conditions

Monitoring Plan

• Weekly complete blood count during treatment
• Monthly vital signs and physical examination
• Continuous adverse event monitoring
• Regular assessment of organ function

Pharmacological Properties

GM-CSF Pharmacology

GM-CSF (granulocyte-macrophage colony-stimulating factor) is a hematopoietic growth factor that stimulates the proliferation and differentiation of myeloid progenitor cells. The recombinant human form (sargramostim) has been FDA-approved since 1991 for various indications including:

• Bone marrow transplantation
• Neutropenia following chemotherapy
• Acute myeloid leukemia
• Myelodysplastic syndrome

Pharmacokinetics

In AD patients, the CNS penetration of systemically administered GM-CSF is a key consideration:

• Peripheral administration: Subcutaneous injection leads to systemic distribution
• CNS penetration: Limited direct penetration across the blood-brain barrier
• Mechanism hypothesis: Effects may be mediated through peripheral immune modulation or via circumventricular organs
• Alternative approaches: Intranasal delivery being explored to enhance CNS targeting

Drug-Drug Interactions

Important interactions to monitor in AD patients:

• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Generally compatible
• Memantine: No known interactions
• Anticoagulants: Potential effects on bleeding risk
• Immunomodulators: Additive or antagonistic effects possible

Regulatory and Development Context

Orphan Drug Potential

GM-CSF for AD may qualify for orphan drug designation:

• Significant unmet need in AD
• Novel mechanism of action
• Potential for substantial benefit in subpopulation

Development Pathway

Regardless of trial outcome, the development pathway includes:

Future Directions

Regardless of trial outcomes, this study advances our understanding of AD pathophysiology and immune modulation:

Combination Therapy Possibilities

Future studies may explore:

• GM-CSF + anti-amyloid antibodies: Enhanced amyloid clearance
• GM-CSF + anti-tau therapies: Targeting multiple pathological proteins
• GM-CSF + TREM2 agonists: Complementary microglial activation
• GM-CSF + cognitive enhancers: Symptomatic and disease-modifying combination

Personalized Medicine Approaches

Biomarker stratification may identify patients most likely to benefit:

• Patients with evidence of microglial dysfunction
• Those with specific amyloid/tau biomarker profiles
• Subgroups with particular genetic risk factors (e.g., TREM2 variants)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Immunotherapy for Alzheimer's](/mechanisms/alzheimers-immunotherapy)
• [Microglia in Neurodegeneration](/mechanisms/microglia-neurodegeneration)
• [Amyloid Clearance Mechanisms](/mechanisms/amyloid-clearance)
• [TREM2 and Microglial Signaling](/mechanisms/trem2-microglia-ad)

External Links

• [ClinicalTrials.gov: NCT04902703](https://clinicaltrials.gov/ct2/show/NCT04902703)
• [GM-CSF Trial Information](https://clinicaltrials.gov/)
• [Leukine (Sargramostim) Prescribing Information](https://www.accessdata.fda.gov/)

References